Bellicum Pharmaceuticals (BLCM) Cut to “Strong Sell” at BidaskClub
BidaskClub lowered shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) from a sell rating to a strong sell rating in a research report report published on Thursday.
A number of other research firms also recently issued reports on BLCM. ValuEngine upgraded Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a research note on Monday, September 18th. Jefferies Group reiterated a buy rating and set a $16.00 price target on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a hold rating to a buy rating and set a $10.00 price target for the company in a research note on Wednesday, January 10th. Finally, Raymond James Financial reiterated a buy rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $23.50.
Bellicum Pharmaceuticals (BLCM) traded up $0.06 during mid-day trading on Thursday, hitting $8.96. The stock had a trading volume of 259,600 shares, compared to its average volume of 426,478. Bellicum Pharmaceuticals has a 1 year low of $7.41 and a 1 year high of $15.55. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08. The company has a market cap of $297.71, a price-to-earnings ratio of -3.00 and a beta of 1.18.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period last year, the business posted ($0.66) earnings per share. The business’s revenue was up 18.2% on a year-over-year basis. equities analysts forecast that Bellicum Pharmaceuticals will post -2.93 earnings per share for the current year.
In related news, CFO Alan A. Musso sold 6,206 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $9.89, for a total value of $61,377.34. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Alan A. Musso sold 17,117 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $9.33, for a total transaction of $159,701.61. Following the completion of the sale, the chief financial officer now directly owns 31,585 shares in the company, valued at approximately $294,688.05. The disclosure for this sale can be found here. Insiders sold a total of 23,810 shares of company stock worth $225,657 in the last 90 days. Company insiders own 18.77% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. Franklin Street Advisors Inc. NC raised its holdings in shares of Bellicum Pharmaceuticals by 293.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 48,285 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 36,000 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Bellicum Pharmaceuticals in the 3rd quarter worth approximately $164,000. Point72 Asset Management L.P. bought a new stake in shares of Bellicum Pharmaceuticals in the 3rd quarter worth approximately $4,723,000. Schwab Charles Investment Management Inc. raised its holdings in shares of Bellicum Pharmaceuticals by 47.1% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock worth $1,516,000 after purchasing an additional 41,995 shares during the period. Finally, Harvey Capital Management Inc. bought a new stake in shares of Bellicum Pharmaceuticals in the 3rd quarter worth approximately $458,000. 55.28% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/bellicum-pharmaceuticals-blcm-cut-to-strong-sell-at-bidaskclub/1808094.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.